David Novak

Item: David Novak
Rating: 0.57
Author: StockAnalysis.com

Stock Analyst at Raymond James

(0.57)

# 4,147

Out of 5,116 analysts

Total ratings

42.86%

Success rate

-13.85%

Average return

Main Sectors:

Top Industries:

Stocks Rated by David Novak

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	ZYME Zymeworks	Downgrades: Outperform	$74	$22.53	+228.45%	6	Dec 10, 2021
	CBIO Crescent Biopharma	Maintains: Outperform	$300 → $270	$9.59	+2,715.43%	1	Feb 4, 2021

Zymeworks

Dec 10, 2021

Downgrades: Outperform

Price Target: $74

Current: $22.53

Upside: +228.45%

Crescent Biopharma

Feb 4, 2021

Maintains: Outperform

Price Target: $300 → $270

Current: $9.59

Upside: +2,715.43%